Aidence has announced a strategic collaboration with AstraZeneca that will provide Aidence's artificial intelligence (AI) software to hospitals across Europe for early lung cancer diagnosis through detection and follow-up of incidental pulmonary nodules.
AstraZeneca will fund a pilot phase to implement Aidence's software in 2021 before expanding to a planned 25 to 30 European hospitals in 2022, with the support of an external steering committee.
This includes developing a protocol for an early lung cancer detection pathway through collaboration with scientific societies, establishing lung nodule clinics, supporting improved patient communication for follow-up, and educating healthcare practitioners and patients. Data assessing the impact of the software will be published periodically by the steering committee.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
